This finding is of particular interest because of the ongoing clinical development of OX-40 agonists, alone or in combination with PD-1/PD-L1 inhibitors, in the treatment of solid tumors including advanced NSCLC. Here, CD274 is linked to non-small cell lung carcinoma.